Revenue and Income - Revenue for the December 2023 quarter was 3,482.1 million in the September 2023 quarter, primarily driven by increased investments in the DRAM market segment[79]. - Net income for the December 2023 quarter was 887.4 million in the September 2023 quarter, resulting in diluted net income per share of 6.66[79]. Gross Margin and Expenses - Gross margin for the December 2023 quarter was 700.2 million, an increase from 631.7 million in the September 2023 quarter, primarily due to higher employee-related costs[79][80]. - Research and Development (R&D) expenses for the three months ended December 24, 2023, were 469,712 thousand, accounting for 12.5% of revenue, up from 12.1% in the previous quarter[87]. - Selling, General, and Administrative (SG&A) expenses for the three months ended December 24, 2023, were 16,645 thousand, representing 0.4% of revenue, an increase from 0.3% in the previous quarter[91]. Cash Flow and Investments - Cash and cash equivalents, investments, and restricted cash and investments increased to 5.2 billion at the end of the September 2023 quarter[81]. - Net cash provided by operating activities for the six months ended December 24, 2023, was 1,841,664 thousand[107]. - Net cash used for investing activities during the six months ended December 24, 2023, was 192.3 million in capital expenditures[108]. - Net cash used for financing activities during the six months ended December 24, 2023, was 1,488.7 million in treasury stock repurchases and 1,928.0 million at the end of the December 2023 quarter, up from 107.1 million for workforce actions associated with a restructuring plan in the second half of fiscal year 2023[77]. Future Outlook and Risks - The company expects to incur expenditures in the range of $300 million for business process improvements and restructuring activities throughout the 2024 fiscal year[77]. - The company expects anticipated cash flows from operations to be sufficient to support operations and investments for at least the next twelve months[110]. - Future liquidity will heavily depend on future revenues and cost management based on product demand[111]. - The company has substantial cash balances but may require additional funding through borrowings or sales of debt/equity securities[111]. - Access to capital markets is expected to be adequate for meeting objectives, though macroeconomic conditions may pose challenges[111]. - Market risk exposure related to interest rates, equity prices, and foreign currency exchange rates has not changed materially since June 25, 2023[112].
Lam Research(LRCX) - 2024 Q2 - Quarterly Report